Novo Nordisk is rebranding to 'Novo' and implementing corporate culture changes as it competes for obesity drug market share against rival Eli Lilly. The Danish drugmaker, facing investor pressure and a 15% stock decline this year, will detail its strategy at a September Capital Markets Day event. Despite successful Wegovy oral launch, Novo holds 38.8% obesity market share compared to Lilly's 60.9%.